Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Diseases
100%
Infection
92%
Plasma Exchange
74%
Erythrocyte
55%
Chimeric Antigen Receptor T-Cell
55%
COVID-19
55%
Infectious Complication
55%
Homologous Recombination
55%
Vascular Disease
55%
Cell Therapy
55%
CAR T-cell therapy
55%
Recombination Repair
55%
Histiocytosis
55%
Prostate Cancer
55%
Leukocyte
55%
Leukemic Infiltration
55%
Conditioning
37%
DNA Repair
37%
Desensitization
37%
Hematologic Malignancy
37%
Acute Myeloid Leukemia
37%
Next Generation Sequencing
37%
Cancer
37%
Neoplasm
29%
Homeostasis
27%
Inflammatory Cytokine
27%
Microangiopathy
27%
Histiocyte
22%
Mitogen-Activated Protein Kinase
22%
Aplasia
18%
BRCA2
18%
Graft Failure
18%
DNA Damage
18%
BRCA1
18%
Lymphocyte
18%
Disease
18%
Acute Myelogenous Leukemia
18%
Double Stranded DNA
18%
PARP Inhibitor
18%
Rituximab
18%
Daratumumab
18%
Engraftment
18%
Immunoglobulin G
18%
Stem Cell Transplant
18%
Targeted Therapy
18%
Cyclophosphamide
18%
Cellular Mechanism
18%
Carboplatin
18%
Androgen
18%
Blood Group A Antibody
18%
Keyphrases
Peri
55%
FcRn Antagonists
55%
Efgartigimod
55%
CAR T-cell Therapy
55%
All-trans Retinoic Acid
55%
ALK-positive Histiocytosis
55%
Viral Hepatitis
55%
Donor-specific Antibodies
55%
Neurologic
55%
Large B-cell Lymphoma
55%
Axicabtagene Ciloleucel
55%
Acute Promyelocytic Leukemia
55%
Angiopathy
55%
Remission
55%
Retinoic Acid Resistance
41%
CNS Involvement
27%
Diffuse Large B-cell Lymphoma (DLBCL)
27%
Twist1
27%
Hepatitis B
27%
RBC Transfusion
22%
Transfusion Independence
22%
Isohemagglutinins
22%
KIF5B-ALK Fusion
22%
Androgen Blockade
18%
KMT2A-MLLT3
18%
Atypical Pneumonia
18%
Silent Disease
18%
Recurrent Disease
13%
Relapsed or Refractory
13%
Inner City
13%
CD19
13%
Line of Therapy
13%
FDA-approved Drugs
13%
Lymphoma
13%
Acid Treatment
13%
Good Prognosis
13%
Tertiary Care Hospital
13%
Bronx
13%
Refractory Diffuse Large B-cell Lymphoma
13%
Chimeric Antigen Receptor T-cell Therapy
13%
Complete Remission
13%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
Poor Graft Function
11%
Anti-A
11%
Engraftment
11%
Allogeneic Transplant
11%
Desensitization Strategies
11%
Median Fluorescent Intensity
11%
Post-transplantation Cyclophosphamide (PTCy)
11%
Haploidentical Donor
11%